Yashoda Super Specialty Kaushambi
The Subject Expert Committee of Drugs Controller General of India (DCGI) on Wednesday recommended Serum Institute’s indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for cervical cancer patients.
“An expert panel of India’s central drug authority on Wednesday recommended granting of market authorisation to Serum Institute of India (SII) indigenously-developed India’s first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer”, said a source.
The vaccine has been recommended for cervical cancer patients those above 9 years to 26 years of age for both male and female.According to the source, an application has also been sent to the National Technical Advisory Group on Immunisation (NTAGI).
The NTAGI may take the final decision on the HPV vaccine in the next meeting scheduled to be held on June 29.
Transcendental Meditation (TM), once known primarily as a personal well-being practice, is now emerging as…
Union health minister JP Nadda on Tuesday unveiled the "Inter-AIIMS Referral" portal, developed indigenously by the…
The lungs are involved by a multitude of causes ranging from congenital to systemic diseases,…
A shocking incident has come to light in the Damoh district of Madhya Pradesh, shaking…
Recognizing the increasing burden of non-communicable diseases (NCDs) and the pivotal role of improving understanding…
The BJP-led Delhi government on Saturday entered into an agreement with the Union health ministry…